Janssen (China) has supported a public welfare program and patient relapse research in Beijing in a bid to help psoriasis patients in China.

The events, launched by Beijing Bethune Charitable Foundation, are aimed at slowing down the recurrence of psoriasis and promoting drug innovation that leads the standardized treatment of the disease.

Psoriasis is a common, chronic, inflammatory, systemic immune-mediated skin disease. Due to the difficulty in treatment and the high risk of recurrence, patients often suffer from the lifelong condition. Epidemiological investigation data showed that, currently in China, there were nearly 7 million psoriasis patients and the incidence of the disease was 0.47 percent.

Wang Xiao'e, first-level counsel of Beijing Municipal Health Commission, said that it is necessary to carry out popular science education and public welfare programs on psoriasis, which is an integral part of the Healthy China 2030 initiative.

Regarding this year's public welfare program, He Xuzheng, vice-president of Janssen China's Immunology and Pulmonary Hypertension Department, said: "As an innovative pharmaceutical company which entered the Chinese market 38 years ago, Janssen has been always committed to providing Chinese patients with high-quality, innovative products."

In the future, Janssen will continue to leverage its advantages and experience in global drug research and development, to strengthen the investment in innovative drug R&D. In addition, it will continue to support the establishment of academic exchange platforms, to promote experience sharing about the disease, said the company.